Topical Tacrolimus in Vernal Keratoconjunctivitis
Launched by THE EYE CENTER AND THE EYE FOUNDATION FOR RESEARCH IN OPHTHALMOLOGY · May 25, 2015
Trial Information
Current as of June 23, 2025
Unknown status
Keywords
ClinConnect Summary
A total of 20 patients with bilateral symmetrical vernal keratoconjunctivitis will be included. Each patient will undergo a complete ophthalmologic evaluation. Patient will be placed at random on topical Tacrolimus 0.01% ophthalmic solution in one eye and placebo eyedrops in the fellow eye. Patients will undergo ophthalmologic examination at one week and after one month. Photos will be taken. The outcome measures include graded symptoms, graded signs, and laboratory investigations. Symptoms of itching, redness, foreign body sensation, tearing and discharge following will be recorded before ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • with bilateral symmetrical palpebral and limbal vernal keratoconjunctivitis
- • Patients 6-18 years of age
- Exclusion Criteria:
- • Pregnant patients
- • Patients on systemic therapy for other allergic disorders
- • Patients who cannot come for follow-up
- • Patients who are on other topical medications for other comorbid ocular conditions
About The Eye Center And The Eye Foundation For Research In Ophthalmology
The Eye Center and the Eye Foundation for Research in Ophthalmology are dedicated organizations committed to advancing the field of ophthalmology through innovative clinical trials and research initiatives. With a focus on improving vision and eye health, they collaborate with leading experts to investigate cutting-edge treatments and technologies. Their mission encompasses not only the enhancement of patient care but also the dissemination of knowledge and findings to the broader medical community, ultimately aiming to transform the landscape of eye care and contribute to the prevention and treatment of ocular diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Patients applied
Trial Officials
Samir S Shoughy
Principal Investigator
THE EYE CENTER
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials